10-Q: Polomar Health Services Reports Widening Losses Amid Business Model Transition and Going Concern Doubts

Polomar Health Services, Inc. reported a significant increase in net loss and continued reliance on related-party financing for the quarter ended March 31, 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• Polomar Health Services, Inc. (formerly Trustfeed Corp.) operates Polomar Specialty Pharmacy, LLC, a Florida-licensed retail compounding pharmacy, and the SlimRxTM online weight loss platform.
• The company is authorized to fulfill and deliver compounded prescribed medications in 28 states and aims to expand to a majority of U.S. states by the end of 2025.
• Revenue for the three months ended March 31, 2025, decreased to $4,542 from $13,610 in the prior year, primarily due to a post-merger transition to an online business model.
• Net loss significantly widened to $456,855 for the three months ended March 31, 2025, compared to a net loss of $160,468 for the same period in 2024.
• Operating expenses surged by approximately 167% to $418,590, driven by amortization ($249,625), SEC filing fees ($36,304), and payroll ($67,568).
• As of March 31, 2025, the company had cash of $129,331 and a working capital deficit of $1,459,182.
• The company relies heavily on related-party loans, with outstanding principal on promissory notes totaling $1,214,131 as of March 31, 2025, plus accrued interest.
• Polomar acquired intellectual property rights from Pinata Holdings, Inc. (an affiliate of CWR) for proprietary delivery of various medications, valued at $9,735,000, though the underlying IP is not yet patent protected.
• A Product Fulfillment and Distribution Agreement with ForHumanity, Inc. grants exclusive marketing rights for inhalable sildenafil and sumatriptan through September 30, 2025, in exchange for a guaranteed payment of $750,000.
• The company identified material weaknesses in its internal control over financial reporting, including inadequate segregation of duties and insufficient written policies and procedures.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to significant financial losses, a worsening working capital deficit, explicit 'going concern' doubt, and identified material weaknesses in internal controls. While there are some positive business developments and strategic plans, the severe financial distress and reliance on related-party funding overshadow them, indicating a high level of risk and instability.

Positives

• Cash on hand increased significantly to $129,331 as of March 31, 2025, from $6,191 at December 31, 2024.
• Net cash used in operating activities decreased to $45,577 for the three months ended March 31, 2025, from $164,763 in the prior year, indicating improved cash burn efficiency from operations.
• The company secured a guaranteed payment of $750,000 through an exclusive marketing agreement with ForHumanity, Inc. for its inhalable sildenafil and sumatriptan products.
• The company has a strategic plan to expand its prescription medication delivery to a majority of U.S. states by the end of 2025 and anticipates applying for a drug export permit in Q3 2025.
• The company expects steady growth in its wholesale prescription fulfillment services for third-party web-based telehealth platforms over the next 12 to 18 months.
• The licensed intellectual property rights are valued at $9,735,000, indicating significant potential asset value for future revenue generation.

Negatives

• Revenue for the three months ended March 31, 2025, significantly decreased to $4,542, down from $13,610 in the same period of 2024.
• Net loss widened substantially to $456,855 for the three months ended March 31, 2025, compared to $160,468 in the prior year period.
• Operating expenses increased by approximately 167% to $418,590 for the three months ended March 31, 2025.
• The company has a significant working capital deficit of $1,459,182 as of March 31, 2025, worsening from $1,260,965 as of March 31, 2024.
• The company has an accumulated deficit of $3,368,018 as of March 31, 2025.
• The company does not have sufficient cash to fund its operations for the next 12 months and relies on related party loans for working capital.
• The intellectual property rights licensed from Pinata Holdings, Inc. are patent pending and have not yet been granted patent protection by the U.S. Patent and Trademark Office.
• The license agreement for the intellectual property is non-exclusive and terminable on 180 days' notice by either party, posing a risk to long-term revenue streams from these assets.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to a history of losses, negative cash flows from operations, and insufficient cash to fund operations for the next 12 months.
• There is no guarantee that the company will raise sufficient additional capital to continue operations.
• The company faces uncertainty regarding profitability due to its history of losses.
• Risks are present related to legislative or regulatory changes concerning platforms with data about companies.
• Uncertainties exist related to the company's business plan and business strategy.
• The company faces risks concerning intellectual property rights, including protecting those rights and potential claims of infringement of others' intellectual property.
• Competition in the compounding pharmacy and telehealth sectors poses a risk.
• Cybersecurity concerns are a potential risk to operations.
• Material weaknesses in internal control over financial reporting exist, specifically inadequate segregation of duties, ineffective risk assessment, and insufficient written policies and procedures for accounting and financial reporting.

Future Outlook

The company plans to continue investing working capital in its newly acquired Polomar business and other potential opportunities. It anticipates expanding prescription medication delivery to a majority of U.S. states by the end of 2025 and applying for a drug export permit in the third quarter of 2025. The launch of PoloMedsTM for diabetes and dermatological medications is expected in the third quarter of 2025. The wholesale segment, providing prescription fulfillment services for third-party telehealth platforms, is projected to experience steady growth over the next 12 to 18 months. Management is actively seeking additional investors to raise capital, as current cash is insufficient for the next 12 months of operations.

Management Comments

• Management believes all adjustments considered necessary for a fair presentation of interim financial information have been included.
• Operating results for the interim period ended March 31, 2025, are not necessarily indicative of the results that can be expected for the full year.
• Management evaluated all relevant conditions and events and determined that substantial doubt exists about the company's ability to continue as a going concern.
• Management plans to raise additional capital and invest working capital resources in its existing business and other potential business opportunities over the next twelve months.
• There is no guarantee the company will raise sufficient capital to continue operations.
• The decrease in revenues was primarily due to the post-merger transition to an online business model.
• The decrease in net cash used in operating activities was due primarily to increased cash receipts prepaid.

Industry Context

Polomar Health Services is positioning itself within the growing compounding pharmacy and telehealth sectors, particularly focusing on weight loss medications (semaglutide) and specialized dermatological and erectile dysfunction treatments. The shift to an online business model aligns with broader trends in healthcare towards digital platforms and direct-to-consumer services. The company's strategy to provide fulfillment services for third-party telehealth platforms indicates an intent to become a key backend provider in the expanding telehealth ecosystem. The focus on compounded medications allows for customized solutions, which can be a competitive advantage in niche markets, but also subjects the company to specific regulatory guidelines (Sec. 503A Compounding Pharmacy of the Federal Food, Drug and Cosmetic Act).

Comparison to Industry Standards

• The company's current revenue of $4,542 for the quarter is extremely low for a publicly traded health services company, especially one with aspirations for national and international reach, indicating it is in a very early stage of commercialization or experiencing significant operational challenges post-transition.
• The substantial net loss of $456,855 and accumulated deficit of over $3.3 million, coupled with a working capital deficit exceeding $1.4 million, are indicative of a company far from industry profitability benchmarks, which typically require significant scale to achieve profitability in the healthcare sector.
• Reliance on related-party debt for funding operations, with over $1.2 million in related party promissory notes due in July 2025, is a common characteristic of early-stage or distressed companies, contrasting with established industry players that typically access broader capital markets or generate sufficient internal cash flow.
• The identified material weaknesses in internal control over financial reporting (inadequate segregation of duties, insufficient policies) fall below standard corporate governance practices for publicly traded companies, which prioritize robust financial controls to ensure accuracy and prevent fraud.
• While the valuation of licensed intellectual property at $9.735 million suggests potential, the non-exclusive, terminable nature of the license and the lack of granted patent protection introduce significant uncertainty compared to companies with fully patented, proprietary technologies.
• The company's expansion into 28 states and plans for a majority of U.S. states by year-end 2025, along with a drug export permit application, indicate an aggressive growth strategy, but this ambition is currently unsupported by its financial performance and capital resources, unlike well-capitalized industry leaders like CVS Health or Walgreens Boots Alliance that have established national footprints.

Management Changes

Corporate Governance

Related Party Transactions

• The company has outstanding promissory notes with Reprise Management, Inc. (Polomar Note) and CWR 1, LLC, both affiliates of Daniel Gordon, who is also affiliated with GLD Partners, LP. As of March 31, 2025, the Polomar Note had an outstanding principal of $808,094.30 plus $58,477.23 in accrued interest, and the CWR 1, LLC Note had an outstanding principal of $406,037.26 plus $24,677.78 in accrued interest. Both notes are due July 31, 2025.
• Daniel Gordon, an affiliate of the company, personally loaned the company $10,000 on January 31, 2025, which was repaid in full by April 1, 2025.
• The company licensed intellectual property rights from Pinata Holdings, Inc., which is an affiliate of CWR 1, LLC, the company's lender and significant shareholder.

Stakeholder Impact

• Shareholders face significant risk of value erosion due to widening losses, substantial doubt about the company's going concern ability, and potential future dilution from capital raises or stock-based compensation.
• Creditors, particularly related parties, are exposed to the risk of non-repayment given the company's liquidity challenges and reliance on further capital raises.
• Employees may face job insecurity or limited growth opportunities due to the company's financial instability and the need to secure additional capital before adding personnel.
• Customers of Polomar Specialty Pharmacy and SlimRxTM may experience uncertainty regarding the long-term viability of services if the company's financial challenges persist.
• Suppliers may face payment delays or reduced business volume if the company's operations are constrained by insufficient capital.

Next Steps

• Polomar Specialty Pharmacy is actively seeking approval and authorization to provide prescription medications in a majority of U.S. states by the end of 2025.
• The company anticipates applying for a drug export permit in the third quarter of 2025.
• The company expects to launch PoloMedsTM (polomeds.com) during the third quarter of 2025 to fulfill prescriptions for diabetes medications, compounded erectile dysfunction medications, and exclusive dermatological formulations.
• Management plans to raise additional capital over the next twelve months.
• Management plans to invest working capital resources in its newly acquired business from Polomar and in other potential business opportunities.
• The company anticipates adding consultants or employees for corresponding operations, but only after obtaining additional capital.
• ForHumanity, Inc. can extend its exclusivity to market inhalable sildenafil and sumatriptan through March 30, 2026, provided it provides at least $1,500,000 in sales revenue to the company this year, with further extensions possible upon meeting increased revenue goals.

Key Dates

Recommendation

Keywords

Polomar Health Services, compounding pharmacy, telehealth, weight loss medications, semaglutide, SlimRx, PoloMeds, SEC filing, 10-Q, financial results, going concern, related party transactions, intellectual property, pharmaceuticals, healthcare, corporate governance